

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**

**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

## **VOLUNTARY ANNOUNCEMENT**

### **DECLARATION MADE FOR POMALIDOMIDE CAPSULES**

This announcement is made by the board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Chia-Tai Tianqing Pharmaceutical Holdings Co. Ltd, a subsidiary of the Company, has made declaration of manufacturing information to the Center for Drug Evaluation of China Food and Drug Administration for the Pomalidomide Capsules (the “**Product**”) developed by it, and the declaration was accepted. The Product is a Chemicals Category 3.1 drug comprising two specifications, 1mg and 4mg, being used for the treatment of multiple myeloma.

Pomalidomide is an analog of thalidomide and an immunomodulator featuring with anti-tumor activity, which can inhibit the proliferation and induce the apoptosis of hematopoietic tumor cells. Pomalidomide can be applied to patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and bortezomib, and have worsened or within 60 days of completion of their last therapy. It can serve as an additional treatment option for patients who have taken other medications that are ineffective to them.

Pomalidomide can be widely applied in treating malignant diseases in future, yet it has currently not been launched in the PRC, rendering it expensive and generally inconvenient for patients to use for treatment. The Group has carried out research on the Product with an aim of offering multiple myeloma patients with affordable drugs and reducing their treatment costs.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairlady*

Hong Kong, 16 August 2018

*As at the date of this announcement, the Board of the Company comprises seven Executive Directors, namely Miss Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.*